The ‘game changing’ results from the RELATIVITY-047 trial were revolutionary and validated the option of LAG-3 blockade, in combination with PD-1 inhibitor, as a therapeutic option for patients with melanoma.28, –30. The gene discussed is LAG3; the disease is melanoma.